Clinical trial

A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis

NCT06551519

StatusACTIVE_NOT_RECRUITING

Study typeOBSERVATIONAL

Start date2024-10-23

PhaseN/A

Study timeline

Study start (actual)2024-10-23Date precision: day

Registry last updated2026-10-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisunresolved

Interventions

ofatumumabOTHER

DMT category 1OTHER

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

BerlinGermany5 MünchenGermany2 HamburgGermany1 DresdenGermany1 EssenGermany1 LeipzigGermany1 MünsterGermany1 UlmGermany1 DüsseldorfGermany1 BonnGermany1 BochumGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06551519 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.